Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene

Cancer Research

Volumn 70, Issue 2, 2010, Pages 762-771

  Schaaf, Gerben ^a,b   Hamdi, Mohamed ^a   Zwijnenburg, Danny ^a   Lakeman, Arjan ^a   Geerts, Dirk ^a   Versteeg, Rogier ^a   Kool, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SPROUTY PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION; NIH 3T3 CELLS; PHOSPHOPROTEINS; RAS PROTEINS; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL;

EID: 76549107087     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2532     Document Type: Article

References (36)

1. Diaz-Flores E, Shannon K. Targeting oncogenic Ras. Genes Dev 2007;21:1989-92.
2. Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 2007;6:2902-5.
3. Christofori G. Split personalities: the agonistic antagonist Sprouty. Nat Cell Biol 2003;5:377-9.
4. Lo TL, Fong CW, Yusoff P, et al. Sprouty and cancer: the first terms report. Cancer Lett 2006;242:141-50.
5. Fong CW, Chua MS, McKie AB, et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006;66:2048-58.
6. Chen Y, Takita J, Hiwatari M, et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 2006;45:583-91.
7. Yoo J, Robinson RA. H-ras and K-ras mutations in soft tissue sarcoma: comparative studies of sarcomas from Korean and American patients. Cancer 1999;86:58-63.
8. Lo TL, Yusoff P, Fong CW, et al. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004;64:6127-36.
9. Lee CC, Putnam AJ, Miranti CK, et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 2004;23:5193-202.
10. Minowada G, Miller YE. Sprouty 2 gene in mouse lung tumorigenesis. Chest 2004;125:111S.
11. Shaw AT, Meissner A, Dowdle JA, et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 2007;21:694-707.
12. Sutterlüty H, Mayer CE, Setinek U, et al. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res 2007;5:509-20.
13. McKie AB, Douglas DA, Olijslagers S, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005;24:2166-74.
14. Wang J, Thompson B, Ren C, Ittmann M, Kwabi-Addo B. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate 2006;66:613-24.
15. Brady SC, Coleman ML, Munro J, et al. Sprouty2 association with BRaf is regulated by phosphorylation and kinase conformation. Cancer Res 2009;69:6773-81.
16. Tsavachidou D, Coleman ML, Athanasiadis G, et al. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 2004;64:5556-9.
17. Schaaf GJ, Ruijter JM, van Ruissen F, et al. Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB J 2005;19:404-6.
18. Revet I, Huizenga G, Chan A, et al. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res 2008;314:707-19.
19. Molenaar JJ, Ebus ME, Geerts D, et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A 2009;106:12968-73.
20. Schaaf GJ, Maas RF, de Groene EM, Fink-Gremmels J. Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. Free Radic Res 2002;36:835-43.
21. Hamdi M, Popeijus HE, Carlotti F, et al. ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses. DNA Repair (Amst) 2008;7:487-96.
22. Jacob D, Davis J, Fang B. Xenograftic tumor models in mice for cancer research, a technical review. Gene Ther Mol Biol 2004;8:213-9.
23. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2) (q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004;64:5539-45.
24. Mason JM, Morrison DJ, Basson MA, Licht JD. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 2006;16:45-54.
25. Ozaki K, Kadomoto R, Asato K, et al. ERK pathway positively regulates the expression of Sprouty genes. Biochem Biophys Res Commun 2001;285:1084-8.
26. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J. Epub 2009 Oct 16.
27. Huebert RC, Li Q, Adhikari N, et al. Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiol Genomics 2004;18:284-9.
28. Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009;106:4519-24.
29. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005;1756:81-2.
30. Bloethner S, Chen B, Hemminki K, et al. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 2005;26:1224-32.
31. Lito P, Mets BD, Appledorn DM, Maher VM, McCormick JJ. Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. J Biol Chem 2009;284:848-54.
32. Lito P, Mets BD, Kleff S, et al. Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. J Biol Chem 2008;283:2002-9.
33. Liu D, Liu Z, Jiang D, Dackiw AP, Xing M. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 2007;92:4686-95.
34. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14:230-9.
35. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93.
36. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46.